CA2393200C - Methods for targeting cells that express fibroblast growth receptor-3 or-2 - Google Patents

Methods for targeting cells that express fibroblast growth receptor-3 or-2 Download PDF

Info

Publication number
CA2393200C
CA2393200C CA2393200A CA2393200A CA2393200C CA 2393200 C CA2393200 C CA 2393200C CA 2393200 A CA2393200 A CA 2393200A CA 2393200 A CA2393200 A CA 2393200A CA 2393200 C CA2393200 C CA 2393200C
Authority
CA
Canada
Prior art keywords
fgf
polypeptide
amino acid
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2393200A
Other languages
English (en)
French (fr)
Other versions
CA2393200A1 (en
Inventor
James W. West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of CA2393200A1 publication Critical patent/CA2393200A1/en
Application granted granted Critical
Publication of CA2393200C publication Critical patent/CA2393200C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA2393200A 1999-12-02 2000-11-28 Methods for targeting cells that express fibroblast growth receptor-3 or-2 Expired - Fee Related CA2393200C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45297799A 1999-12-02 1999-12-02
US09/452,977 1999-12-02
PCT/US2000/032380 WO2001039788A2 (en) 1999-12-02 2000-11-28 Methods for targeting cells that express fibroblast growth receptor-3 or-2

Publications (2)

Publication Number Publication Date
CA2393200A1 CA2393200A1 (en) 2001-06-07
CA2393200C true CA2393200C (en) 2011-07-12

Family

ID=23798734

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2393200A Expired - Fee Related CA2393200C (en) 1999-12-02 2000-11-28 Methods for targeting cells that express fibroblast growth receptor-3 or-2

Country Status (7)

Country Link
EP (1) EP1234033B1 (de)
JP (2) JP5209161B2 (de)
AT (1) ATE539157T1 (de)
AU (1) AU1804201A (de)
CA (1) CA2393200C (de)
ES (1) ES2377935T3 (de)
WO (1) WO2001039788A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043234A1 (en) 1996-10-16 2005-02-24 Deisher Theresa A. Novel FGF homologs
IL139380A0 (en) 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
IL149562A0 (en) 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
AU2003279835B2 (en) 2002-10-07 2009-09-10 Zymogenetics, Inc. Methods of administering FGF18
US20040229292A1 (en) * 2002-11-26 2004-11-18 Sebastiano Cavallaro Use of FGF-18 in the diagnosis and treatment of memory disorders
US7803777B2 (en) 2003-03-14 2010-09-28 Biogenerix Ag Branched water-soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
MXPA05010773A (es) 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
US7067123B2 (en) 2003-04-29 2006-06-27 Musculoskeletal Transplant Foundation Glue for cartilage repair
US7901457B2 (en) 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
US20060009389A1 (en) 2004-07-06 2006-01-12 Moore Emma E Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
US7837740B2 (en) 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
EP2586456B1 (de) 2004-10-29 2016-01-20 ratiopharm GmbH Umformung und GlycoPEGylierung des Fibroblastenwachstumsfaktors (FGF)
SI1828239T1 (sl) * 2004-12-10 2011-11-30 Zymogenetics Inc Proizvodnja fgf18 v prokariotskih gostiteljih
EP2514757A3 (de) 2005-01-10 2014-03-05 ratiopharm GmbH Glycopegylierter Granulozyten-Kolonie stimulierende Faktor
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1891231A4 (de) 2005-05-25 2011-06-22 Novo Nordisk As Glykopegylierter faktor ix
US7815926B2 (en) 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
EP1926459B1 (de) 2005-09-19 2015-01-07 Histogenics Corporation Zellunterstützende matrix mit eng definierter, gleichmässig senkrecht und nicht zufällig organisierter porosität und porendichte und verfahren zur herstellung davon
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
WO2008011633A2 (en) 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
KR101419961B1 (ko) * 2006-08-25 2014-07-30 아레스 트레이딩 에스.에이. Fgf-18 로 연골 질환의 치료
US8962556B2 (en) 2006-09-28 2015-02-24 Prochon Biotech Ltd. FGF-2 variants having N-terminal deletions and increased receptor selectivity and uses thereof
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
US8435551B2 (en) 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
US8685107B2 (en) 2007-07-03 2014-04-01 Histogenics Corporation Double-structured tissue implant and a method for preparation and use thereof
US20090054984A1 (en) 2007-08-20 2009-02-26 Histogenics Corporation Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
RU2573587C2 (ru) 2008-02-27 2016-01-20 Ново Нордиск А/С Конъюгированные молекулы фактора viii
EP2265220A1 (de) 2008-03-05 2010-12-29 Musculoskeletal Transplant Foundation Spongiosa-konstrukte, knorpelteilchen und kombinationen von spongiosa-konstrukten und knorpelteilchen
WO2012038953A2 (en) 2010-09-21 2012-03-29 Hepacore Ltd. Fgf-18 truncated variants having increased receptor specificity and uses thereof
WO2012140650A2 (en) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637677A (en) 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5191067A (en) * 1989-04-27 1993-03-02 The Salk Institute For Biological Studies Fibroblast growth factor conjugates
US5208146A (en) 1990-11-05 1993-05-04 The Regents Of The University Of California Murine monoclonal anti-idiotype antibodies
US5911995A (en) * 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
FR2742662B1 (fr) * 1995-12-21 1998-01-23 Centre Nat Rech Scient Anticorps anti-idiotypiques du facteur de croissance endotheliale vasculaire et leur utilisation comme medicaments
PT931148E (pt) * 1996-10-16 2006-06-30 Zymogenetics Inc Homologos do factor de crescimento fibroblastico

Also Published As

Publication number Publication date
ES2377935T3 (es) 2012-04-03
AU1804201A (en) 2001-06-12
JP5209161B2 (ja) 2013-06-12
WO2001039788A2 (en) 2001-06-07
EP1234033A2 (de) 2002-08-28
JP2003515567A (ja) 2003-05-07
ATE539157T1 (de) 2012-01-15
JP2011140520A (ja) 2011-07-21
WO2001039788A3 (en) 2002-01-31
EP1234033B1 (de) 2011-12-28
CA2393200A1 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
CA2393200C (en) Methods for targeting cells that express fibroblast growth receptor-3 or-2
US7393684B2 (en) Immunoconjugates of anti-IL-20 antibodies and hybridoma cell lines expressing anti-IL-20 antibodies
EP1234035B1 (de) Menschliches zytokinrezeptor
US20080131931A1 (en) Mouse cytokine receptor zcytor16
CA2378519C (en) Human cytokine receptor
EP1373508B1 (de) Menschlicher cytokin-rezeptor
US7470665B2 (en) Methods for targeting cells that express fibroblast growth receptor-3 or -2
AU2007235212A1 (en) Truncated IL-17RA soluble receptor and methods of using in inflammation
HK1115607B (en) Human cytokine receptor

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20181128